Brainsway Ltd (BWAY) - Total Liabilities

Latest as of March 2026: $41.20 Million USD

Based on the latest financial reports, Brainsway Ltd (BWAY) has total liabilities worth $41.20 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Brainsway Ltd (BWAY) long-term investment share to see how much of total assets are deployed in long-term investments.

Brainsway Ltd - Total Liabilities Trend (2000–2025)

This chart illustrates how Brainsway Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Brainsway Ltd balance sheet assets.

Brainsway Ltd Competitors by Total Liabilities

The table below lists competitors of Brainsway Ltd ranked by their total liabilities.

Company Country Total Liabilities
Shanghai Material Trading Co Ltd A
SHG:600822
China CN¥551.18 Million
Arvinas Inc
NASDAQ:ARVN
USA $112.90 Million
Zhejiang Gongdong Medical Technology Co Ltd
SHG:605369
China CN¥451.25 Million
Zhejiang Xiantong Rubber&Plastic Co Ltd
SHG:603239
China CN¥400.42 Million
Northern Arc Capital Ltd
NSE:NORTHARC
India Rs131.17 Billion
Quanta Storage
TWO:6188
Taiwan NT$6.21 Billion
Xinjiang Ba Yi Iron & Steel Co Ltd
SHG:600581
China CN¥29.36 Billion
Nexpoint Residential Trust Inc
NYSE:NXRT
USA $1.60 Billion

Liability Composition Analysis (2000–2025)

This chart breaks down Brainsway Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Brainsway Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.34 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.54 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Brainsway Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Brainsway Ltd (2000–2025)

The table below shows the annual total liabilities of Brainsway Ltd from 2000 to 2025.

Year Total Liabilities Change
2025-12-31 $39.70 Million +24.04%
2024-12-31 $32.00 Million +49.61%
2023-12-31 $21.39 Million +12.11%
2022-12-31 $19.08 Million +3.66%
2021-12-31 $18.41 Million +28.03%
2020-12-31 $14.38 Million -0.96%
2019-12-31 $14.52 Million -12.82%
2018-12-31 $16.65 Million +16.36%
2017-12-31 $14.31 Million +47.87%
2016-12-31 $9.68 Million +3.52%
2015-12-31 $9.35 Million -8.30%
2014-12-31 $10.19 Million +219.03%
2013-12-31 $3.20 Million +14.95%
2012-12-31 $2.78 Million -92.03%
2000-12-31 $34.88 Million --

About Brainsway Ltd

NASDAQ:BWAY USA Medical Devices
Market Cap
$542.98 Million
Market Cap Rank
#11890 Global
#3007 in USA
Share Price
$13.53
Change (1 day)
+0.52%
52-Week Range
$11.59 - $26.04
All Time High
$26.04
About

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, … Read more